2013 | 2012 | |||||||
Compensation | $ | 261.7 | $ | 170.3 | ||||
Rebates, distributor chargebacks and distributor services | 217.3 | 187.0 | ||||||
Clinical trial costs and grants | 192.6 | 183.3 | ||||||
Common share repurchases | 45.7 | 41.0 | ||||||
Interest | 49.0 | 26.3 | ||||||
Royalties, license fees and collaboration agreements | 52.4 | 19.4 | ||||||
Commercial related activities | 46.6 | 22.8 | ||||||
Sales returns | 15.5 | 13.3 | ||||||
Rent | 14.8 | 9.5 | ||||||
Professional services | 9.3 | 9.8 | ||||||
Other Taxes | 7.6 | 8.3 | ||||||
Other | 88.6 | 84.7 | ||||||
Total | $ | 1,001.1 | $ | 775.7 | ||||
2013 | 2012 | |||||||
Contingent value rights – Abraxis acquisition | $ | — | $ | 277.4 | ||||
Sales, use and value added tax | 50.9 | 56.9 | ||||||
Foreign exchange contracts | 55.9 | 33.3 | ||||||
Collaboration agreement | 7.0 | 17.0 | ||||||
Contingent consideration – Avila acquisition | 62.7 | 17.4 | ||||||
Other | 23.2 | 29.3 | ||||||
Total | $ | 199.7 | $ | 431.3 | ||||
2013 | 2012 | |||||||
Contingent consideration – Avila acquisition | $ | 147.5 | $ | 163.5 | ||||
Deferred compensation and long-term incentives | 127.2 | 99.2 | ||||||
Contingent value rights - Abraxis acquisition | 118.1 | — | ||||||
Foreign exchange contracts | 89.6 | 0.6 | ||||||
Deferred lease incentive | 28.7 | 31.4 | ||||||
Collaboration agreement | 28.0 | — | ||||||
Contingent consideration – Gloucester acquisition | 18.3 | 17.3 | ||||||
Manufacturing facility purchase | 13.9 | 14.4 | ||||||
Other | 11.4 | 29.1 | ||||||
Total | $ | 582.7 | $ | 355.5 | ||||